Online inquiry

IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2717MR)

This product GTTS-WQ2717MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD19&CD3E gene. The antibody can be applied in Diffuse Large B Cell Lymphoma (DLBCL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_001178098.2; NM_000733.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930; 916
UniProt ID P15391; P07766
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ2717MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9786MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA JS002
GTTS-WQ10067MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA L19TNF
GTTS-WQ2253MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ALX-0171
GTTS-WQ7239MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FP-1302
GTTS-WQ3631MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ13723MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RC48-0
GTTS-WQ2019MR IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AGT-181
GTTS-WQ7994MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GX-H9
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW